Buy Stalevo (Levodopa with Carbidopa and Entacapone) online

Buy Stalevo (Levodopa with Carbidopa and Entacapone) for Parkinson's disease
Cheap qualitative Carbidopa, Levodopa, Entacapone 25/100/200 mg tablets online



Individual Stalevo tablets should not be fractionated and only one tablet should be administered at each dosing interval.

Generally speaking, Stalevo (Carbidopa/Levodopa/Entacapone) should be used as a substitute for patients already stabilized on equivalent doses of carbidopa-levodopa and entacapone. However, some patients who have been stabilized on a given dose of carbidopa-levodopa may be treated with Stalevo if a decision has been made to add entacapone (see below).

The optimum daily dosage of Stalevo must be determined by careful titration in each patient. Stalevo tablets are available in six strengths, each in a 1:4 ratio of carbidopa to levodopa and combined with 200 mg of entacapone in a standard release formulation (Stalevo 50 containing 12.5 mg of carbidopa, 50 mg of levodopa and 200 mg of entacapone; Stalevo 75, containing 18.75 mg of carbidopa, 75 mg of levodopa and 200 mg of entacapone; Stalevo 100 containing 25 mg of carbidopa, 100 mg of levodopa and 200 mg of entacapone; Stalevo 125, containing 31.25 mg of carbidopa, 125 mg of levodopa and 200 mg of entacapone; Stalevo 150 containing 37.5 mg of carbidopa, 150 mg of levodopa and 200 mg of entacapone; and Stalevo 200 containing 50 mg of carbidopa, 200 mg of levodopa and 200 mg of entacapone).

Therapy should be individualized and adjusted according to the desired therapeutic response.

Studies show that peripheral dopa decarboxylase is saturated by carbidopa at approximately 70 mg to 100 mg a day. Patients receiving less than this amount of carbidopa are more likely to experience nausea and vomiting. Clinical experience with daily doses above 1600 mg of entacapone is limited. It is recommended that no more than one Stalevo tablet be taken at each dosing administration.

Thus the maximum recommended daily dose of Stalevo 50, Stalevo 75, Stalevo 100, Stalevo 125 and Stalevo 150, defined by the maximum daily dose of entacapone, is eight tablets per day. Because there is limited experience with total daily doses of carbidopa greater than 300mg, the maximum recommended daily dose of Stalevo 200 is six tablets per day.

How to transfer patients taking carbidopa-levodopa preparations and Comtan (Entacapone) tablets to Stalevo (Carbidopa/Levodopa/Entacapone) tablets

There is no experience in transferring patients currently treated with formulations of carbidopa-levodopa other than immediate-release carbidopa-levodopa with a 1:4 ratio (controlled-release formulations, or standard-release presentations with a 1:10 ratio of carbidopa-levodopa) and entacapone to Stalevo.

Patients who are currently treated with Comtan 200 mg tablet with each dose of standard-release carbidopa-levodopa, can be directly switched to the corresponding strength of Stalevo containing the same amounts of levodopa and carbidopa. For example, patients receiving one tablet of standard-release carbidopa-levodopa 25/100 mg and one tablet of Comtan 200 mg at each administration can be switched to a single Stalevo 100 tablet (containing 25 mg of carbidopa, 100 mg of levodopa and 200 mg of entacapone).

How to transfer patients not currently treated with Comtan (Entacapone) tablets from carbidopa-levodopa to Stalevo (Levodopa with Carbidopa and Entacapone) tablets

In patients with Parkinson's disease who experience the signs and symptoms of end-of-dose "wearing-off" on their current standard-release carbidopa-levodopa treatment, clinical experience shows that patients with a history of moderate or severe dyskinesias or taking more than 600 mg of levodopa per day are likely to require a reduction in daily levodopa dose when entacapone is added to their treatment. Since dose adjustment of the individual components is impossible with fixed-dose products, it is recommended that patients first be titrated individually with a carbidopa-levodopa product (ratio 1:4) and an entacapone product, and then transferred to a corresponding dose of Stalevo once the patient's status has stabilized.

In patients who take a total daily levodopa dose up to 600 mg, and who do not have dyskinesias, an attempt can be made to transfer to the corresponding daily dose of Stalevo. Even in these patients, a reduction of carbidopa-levodopa or entacapone may be necessary however, the provider is reminded that this may not be possible with Stalevo. Since entacapone prolongs and enhances the effects of levodopa, therapy should be individualized and adjusted if necessary according to the desired therapeutic response.

Maintenance of Stalevo Treatment

Therapy should be individualized and adjusted for each patient according to the desired therapeutic response.

When less levodopa is required, the total daily dosage of carbidopa-levodopa should be reduced by either decreasing the strength of Stalevo at each administration or by decreasing the frequency of administration by extending the time between doses.

When more levodopa is required, the next higher strength of Stalevo should be taken and/or the frequency of doses should be increased, up to a maximum of 8 times daily of Stalevo 50, Stalevo 75, Stalevo 100, Stalevo 125 and Stalevo 150, and maximum of 6 times daily of Stalevo 200.

Addition of Other Antiparkinsonian Medications

Standard drugs for Parkinson's disease may be used concomitantly while Stalevo is being administered, although dosage adjustments may be required.

Interruption of Therapy

Sporadic cases of a symptom complex resembling Neuroleptic Malignant Syndrome (NMS) have been associated with dose reductions and withdrawal of levodopa preparations. Patients should be observed carefully if abrupt reduction or discontinuation of Stalevo is required, especially if the patient is receiving neuroleptics.

If general anesthesia is required, Stalevo may be continued as long as the patient is permitted to take fluids and medication by mouth. If therapy is interrupted temporarily, the patient should be observed for symptoms resembling NMS, and the usual daily dosage may be administered as soon as the patient is able to take oral medication.

Special Populations

Patients with impaired hepatic function

Patients with hepatic impairment should be treated with caution. The AUC and Cmax of entacapone approximately doubled in patients with documented liver disease, compared to controls. However, these studies were conducted with single-dose entacapone without levodopa/dopa decarboxylase inhibitor coadministration, and therefore the effects of liver disease on the kinetics of chronically administered entacapone have not been evaluated.

Recent posts:

  • Buy Stalevo (Carbidopa, Levodopa, Entacapone) Online
  • Stalevo prescribing information

    Copyright © Buy Stalevo (Levodopa with Carbidopa and Entacapone) Online